Cargando…

Combination Erlotinib-Cisplatin and Atg3-Mediated Autophagy in Erlotinib Resistant Lung Cancer

Tyrosine kinase inhibitors such as erlotinib are commonly used as a therapeutic agent against cancer due to its relatively low side-effect profile and, at times, greater efficacy. However, erlotinib resistance (ER) in non-small cell lung cancer is being recognized as a major problem. Therefore, unde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jasmine G., Wu, Reen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3485310/ https://www.ncbi.nlm.nih.gov/pubmed/23119048 http://dx.doi.org/10.1371/journal.pone.0048532

Ejemplares similares

Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo
por: Lee, Jasmine G., et al.
Publicado: (2015)

Effect of erlotinib combined with cisplatin on IL-6 and IL-12 in mice with Lewis lung cancer
por: Zhang, Xu, et al.
Publicado: (2020)

The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Intrinsic caspase-8 activation mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors combination treatment
por: Orzáez, M, et al.
Publicado: (2012)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Erlotinib Resistance in Lung Cancer: Current Progress and Future Perspectives
por: Tang, Joy, et al.
Publicado: (2013)

PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs
por: Lypova, Nadiia, et al.
Publicado: (2021)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma
por: Zhuang, Hongqing, et al.
Publicado: (2016)

Repurposing sertraline sensitizes non–small cell lung cancer cells to erlotinib by inducing autophagy
por: Jiang, Xingwu, et al.
Publicado: (2018)

Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC
por: Bahce, Idris, et al.
Publicado: (2016)

Erlotinib Induced Trichomegaly of the Eyelashes
por: Jeon, Sang-Hoon, et al.
Publicado: (2013)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

NCAPG2 Maintains Cancer Stemness and Promotes Erlotinib Resistance in Lung Adenocarcinoma
por: Jiang, Shiyao, et al.
Publicado: (2022)

Role of erlotinib in the management of pancreatic cancer
por: Starling, Naureen, et al.
Publicado: (2006)

Erlotinib in the treatment of advanced pancreatic cancer
por: Kelley, Robin K, et al.
Publicado: (2008)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
por: Tang, Z, et al.
Publicado: (2008)

IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib
por: Fernando, Romaine I., et al.
Publicado: (2016)

Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668)
por: Yang, Haihong, et al.
Publicado: (2017)

Erlotinib-induced dry eye
por: Ravisankar, Rashmita, et al.
Publicado: (2023)

Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®))
por: Owczarczyk-Saczonek, Agnieszka, et al.
Publicado: (2013)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Radiotherapy and Erlotinib Combined: Review of the Preclinical and Clinical Evidence
por: Mehta, Vivek K.
Publicado: (2012)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011)

YAP promotes erlotinib resistance in human non-small cell lung cancer cells
por: Hsu, Ping-Chih, et al.
Publicado: (2016)

Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer
por: Pal, A.S., et al.
Publicado: (2020)

A mixed treatment comparison of Erlotinib vs. placebo and Erlotinib vs. Geftinib using Bayesian approaches
por: Khan, Iftekhar, et al.
Publicado: (2013)

Erlotinib hydrochloride: an anticancer agent
por: Selvanayagam, S., et al.
Publicado: (2008)

Review of erlotinib in the treatment of advanced non-small cell lung cancer
por: Ganjoo, Kristen N, et al.
Publicado: (2007)

Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy
por: Fatani, Wafa K., et al.
Publicado: (2023)

Exosomal Transfer of lncRNA H19 Promotes Erlotinib Resistance in Non-Small Cell Lung Cancer via miR-615-3p/ATG7 Axis
por: Pan, Rongtao, et al.
Publicado: (2020)

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer
por: Makris, Demosthenes, et al.
Publicado: (2007)

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
por: Liu, Lingli, et al.
Publicado: (2020)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Cutaneous Leukocytoclastic Vasculitis Associated with Erlotinib
por: Sawada, Takahiro, et al.
Publicado: (2016)

Toxicité cutanée à l'erlotinib
por: Bourra, Hayat, et al.
Publicado: (2013)

Stability and Formulation of Erlotinib in Skin Creams
por: Nguyen, David, et al.
Publicado: (2022)

Suppression of c-MET overcomes erlotinib resistance in tongue cancer cells
por: Huang, Keqiang, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4j86oo4atuvq9rdjql1e0vtfl5